ABSTRACT

Objective: To investigate mean platelet volume (MPV) levels in patients with coronary slow flow (CSF).

Methods: 465 stable angina pectoris cases with angiographically normal coronary arteries were recruited [coronary slow flow group (n=76), control group (n=389)] in the observational retrospective cohort study. Clinical, biochemical and demographic variables including MPV were noted and coronary blood flow was assessed with TIMI frame count (TFC).

Results: Gender, smoking, height, serum creatinine, uric acid levels, hemoglobin, waist/hip ratio, systolic blood pressure but not MPV were significantly different among groups. Independent predictors of CSF were height (p=.029) and serum uric acid level (p=.045). Gender, height, weight, hip circumference, systolic blood pressure, fasting blood glucose, serum urea, creatinine, uric acid levels, hemoglobin and platelet count were associated with mean TFC whereas independent predictors of mean TIMI frame count were height (p=.010) and serum uric acid level (p=.041).

Conclusion: Height and serum uric acid level but not MPV were independent predictors of both CSF and mean TFC.

Key words: mean platelet volume, coronary slow flow, stable angina pectoris, regression analysis

Introduction

Coronary slow flow (CSF) is an angiographic concept which is characterized by delayed opacification of the epicardial coronary arteries in the presence of a normal coronary angiogram. CSF is evaluated with precise and reproducible Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) method that counts the number of cineangiographic frames from initial contrast opacification of the proximal coronary artery to opacification of distal arterial landmarks. Although the exact mechanism of CSF is still not clear, diffuse atherosclerosis, inflammatory, oxidative factors and endothelial vasomotor dysfunction have been suggested as possible responsible factors (1-3). Platelet function disorders have also been suggested to be involved in the development of CSF, as well (4, 5). Mean platelet volume (MPV) is an indicator of platelet activation and was postulated to play role in the pathophysiology of coronary artery disease (CAD) (6, 7). In previous studies, increased MPV was demonstrated in acute myocardial infarction, unstable angina pectoris, congestive heart failure, non-dipper hypertension and coronary artery ectasia (6-8).

Although based upon these putative relationships between heart diseases and MPV, a limited number of studies have been performed yet to demonstrate the association of CSF with MPV. Beyond these studies, we aimed to investigate whether MPV levels increased or not within a larger sample size of CSF patients with stable angina pectoris (SAP).

Methods

Study design

This observational retrospective cohort study was conducted at Harran University School of Medicine, Şanlıurfa, Turkey. The study protocol was reviewed and approved by the local ethics committee, in accordance with the ethical principles for human investigations, as outlined by the Second Declaration of Helsinki. Consecutively 465 patients with SAP who underwent elective coronary angiography, on suspicion of CAD, during a
3-year period and were diagnosed as having angiographically normal (0% stenosis) coronary arteries were recruited for the study. The indications for coronary angiography were established with myocardial ischemia suggestive findings on non-invasive tests (exercise stress electrocardiography or nuclear cardiac imaging) besides the presence of typical angina pectoris. All patients were in Canadian Cardiovascular Society (CCS) class 2 or 3.

**Determination of study sample size**

Sample size was calculated according to the results of the first thirteen patients in each study groups, from whom we observed a difference of 5.76% in MPV with a standard deviation of 9.14% between groups. From these differences and assuming a two-tailed $\alpha$ value of 0.05 (sensitivity 95%) and a $\beta$ value 0.20 (study power: 80%), we determined that at least 34 patients were required in each group.

To include 34 CSF cases we have reviewed angiography of 500 cases. Of these 500 cases 35 were excluded due to several reasons [extremes of heart rate (8 cases), different catheter size (6 cases), suboptimal angiographic images (6 cases) and other reasons (5 cases)]. As a result 465 cases with normal coronary arteries were included in the analysis and TIMI evaluation revealed CSF in 76 cases and normal coronary blood flow (CBF) in 389 cases.

**Study population**

Patients were divided into 2 groups; group 1 (n=76) consisted of patients who had SAP with CSF and group 2 (n=389) consisted of patients who had SAP without CSF. The exclusion criteria were as follows: CAD; acute coronary syndromes on admission; history of myocardial infarction; left ventricular dysfunction, left ventricular hypertrophy; atrial fibrillation and valvular, myocardial or pericardial disease. Patients with renal dysfunction (creatinine ≥1.5 mg/dL); hepatic and hemolytic disorders; concomitant inflammatory diseases such as infections and autoimmune disorders, neoplastic diseases; recent major surgical procedure and/or any systemic diseases, and patients taking nitrates, diuretics and uric acid-lowering agents were also excluded from the study.

**Baseline definitions and measurements**

Baseline demographic and clinical variables such as age, gender, height, weight, waist circumference, hip circumference, heart rate, systolic and diastolic blood pressure, personal history of hypertension, and diabetes mellitus and family history of coronary heart disease, and current use of medications were gathered from institutional records. Body mass index was calculated as the weight in kilograms divided by the height in meters squared (kg/m²).

**Evaluation of coronary blood flow**

All participants underwent selective coronary angiography with the Judkins technique using the Philips Angioscop Xray (Integris HM3000, Philips Medical Systems, Best, The Netherlands). Two observers blinded to the clinical details of the individual participants independently quantified the coronary flow using the TFC as previously described (9). The TFC in the left anterior descending coronary artery (LAD) and left circumflex artery (LCx) was assessed in a right anterior oblique projection with caudal angulation, and the right coronary artery (RCA) was assessed in a left anterior oblique projection with cranial angulation. The number of cineangiographic frames, recorded at 25 frames/s, required for the leading edge of the column of radiographic contrast to reach a predetermined distal landmark was determined. The first frame was defined as the frame in which concentrated dye occupies the full width of the proximal coronary artery lumen, touching both borders of the lumen, and indicates forward motion down the artery. The final frame counted was that in which the contrast first reaches the distal predefined landmark branch without the necessity for full opacification. These landmarks were as follows (9). The distal bifurcation of the LAD (i.e. the mustache, pitchfork or whale’s tail) for LAD, the distal branch of the lateral left ventricular wall artery with the longest total distance from the coronary ostium for the LCx, and the first branch of the posterolateral artery for the RCA. If one of these landmarks was not visualized properly, another well visualized landmark close to these landmarks was chosen. Study participants with a TFC greater than two standard deviations from the normal published range for any one of the three vessels (>40.6 frames for LAD, >29.8 frames for LCx and >27.3 frames for RCA) were accepted as having CSF (9). Accordingly, 76 participants were grouped as the SAP with CSF group and 389 participants as the SAP without CSF in our study. As the normal frame counts for the LAD are 1.7 times the mean for the LCx and the RCA, the LAD frame counts were corrected by dividing by 1.7 to derive the corrected TFC (9). The mean TFC for each participant was calculated by adding the TFCs for the corrected LAD, LCx and RCA and then dividing the sum by three. The inter and intra assay CVs were respectively 7% and 3%.

**Biochemical variables**

Biochemical variables (assessed on index admission) such as fasting glucose, triglyceride (TG), total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol and uric acid, white blood cell and platelet count, hemoglobin level, mean corpuscular hemoglobin, mean corpuscular volume and MPV were also gathered from institutional records.

Commercially-available assay kits (Abbott®, Abbott Park, North Chicago, Illinois, USA) with an auto-analyzer (Abbott®, Abbott Park, North Chicago, Illinois, USA) is used for biochemical analysis. In our institutions, MPV is measured in blood samples collected in EDTA tubes, which are analyzed by Abbott Cell-Dyne 4000 cell counter (Abbott®, Abbott Park, North Chicago, Illinois, USA). The normal value range for MPV in our laboratory was 6.8-10.8 fL.

Timing of MPV measurement must be within 120 minutes after venipuncture to avoid MPV increase caused by EDTA. Our study is in a retrospective design. So it is unlikely to say an absolute timing
for MPV measurement. However, in our clinic, analyzing of blood samples takes about one hour after venopuncture for the complete blood count. Namely, although this is a retrospective study, we may say that measurement of MPV values ended up within one hour after blood sampling in nearly all patients. In addition, we suggest that our patients should leave eating, drinking and smoking 6-h before angiography procedure. So, we think that optimal conditions were present for MPV measurement in our patients.

Statistical analysis
All statistical analyses were performed using SPSS for Windows version 11.5 (SPSS, Chicago, IL, USA). Kolmogorov-Smirnov tests were used to test the normality of data distribution. Continuous variables were expressed as mean ± standard deviation and categorical variables were expressed as percentages. Comparisons of categorical and continuous variables between the two groups were performed using the chi-square test and independent samples t-test, respectively. To determine independent predictors of CSF, multiple logistic regression analysis was performed by including the parameters, which were significantly different between the CSF and control groups. Odds ratio (OR), 95% confidence interval (CI) values and their significance from multiple logistic regression analysis were reported. The correlation between mean TFC

| Table 1. Baseline clinical and laboratory characteristics of normal coronary flow and slow coronary slow flow (CSF) groups |
| --- |
| | SAP with CSF (n=76) | SAP without SCF (n=389) | P* Value | OR | 95% CI | P# Value |
| Age, year | 51.8±12.10 | 53.0±10.80 | .350 |
| Gender [Female], n (%) | 35.50 | 60.40 | <.001 | 2.00 | .627-6.385 | .241 |
| Hypertension, n (%) | 44.00 | 45.20 | .899 |
| Diabetes mellitus, n (%) | 14.50 | 15.20 | 1.0 |
| Smoking, n (%) | 47.40 | 30.30 | .005 | .47 | .211-1.058 | .068 |
| Height, m | 1.68±0.11 | 1.63±0.11 | <.001 | 165 | 1.67-16.321 | .029 |
| Weight, kg | 73.6±14.80 | 70.1±14.2 | .057 |
| BMI, kg/m² | 26.2±5.70 | 26.4±5.10 | .845 |
| Waist circumference, m | 0.93±0.13 | 0.94±0.11 | .702 |
| Hip circumference, m | 0.90±0.13 | 0.88±0.11 | .139 |
| Waist/hip ratio | 1.04±0.08 | 1.07±0.08 | .008 | .084 | .001-6.634 | .267 |
| SBP, mm Hg | 126.1±24.5 | 134.3±26.9 | .021 | .986 | .97-1.001 | .071 |
| DBP, mm Hg | 74.8±13.70 | 77.6±13.10 | .115 |
| Heart rate, bpm | 76.4±12.40 | 79.2±11.90 | .075 |
| Fasting blood glucose, mg/dL | 114.9±57.4 | 112.2±47.2 | .672 |
| Total cholesterol, mg/dL | 186.9±54.0 | 190.5±45.7 | .537 |
| Triglyceride, mg/dL | 186.5±126.5 | 175.8±135.6 | .532 |
| HDL cholesterol, mg/dL | 38.10±9.50 | 40.00±11.00 | .185 |
| LDL cholesterol, mg/dL | 114.3±40.0 | 118.1±38.8 | .482 |
| Urea, mg/dL | 38.7±15.50 | 35.0±14.30 | .045 |
| Creatinine, mg/dL | 0.95±0.24 | 0.86±0.20 | <.001 | 5.711 | .631-51.7 | .121 |
| Uric acid, mg/dL | 5.28±1.60 | 4.60±1.54 | .001 | 1.327 | 1.006-1.749 | .045 |
| WBC count, x10⁶/L | 8482±1941 | 8000±2226 | .079 |
| Hemoglobin, g/dL | 14.20±1.60 | 13.80±1.60 | .016 | 1.078 | .809-1.437 | .609 |
| MCH, pg/cell | 30.4±2.50 | 29.7±2.60 | .043 | 1.036 | .821-1.306 | .767 |
| MCV, fl | 86.00±5.30 | 84.30±5.90 | .036 | 1.019 | .914-1.137 | .733 |
| Platelet count, x10⁹/L | 274.8±73.3 | 275.7±69.3 | .916 |
| MPV, fl | 8.73±1.27 | 8.76±1.43 | .881 |

All measurable values were given with mean±standard deviation; categorical variables were given with percentage.
P* Value = Comparison of baseline clinical and laboratory characteristics between normal coronary flow and coronary slow flow (SCF) groups
P# Value= Multiple logistic regression analysis for the parameters which were significantly different between the CSF and control groups.
A two-sided P value < .05 was considered statistically significant.
BMI - body mass index; DBP - diastolic blood pressure; HDL - high density lipoprotein; LDL - low density lipoprotein; MCH - mean corpuscular hemoglobin; MCV - mean corpuscular volume; MPV - mean platelets volume; SAP - stable angina pectoris; SBP - systolic blood pressure; WBC - white blood cell.
and clinical laboratory parameters was assessed by the Pearson’s correlation test. Multiple linear regression analysis was performed to identify the independently associated parameters of mean TFC by including the parameters that were correlated with mean TFC in bivariate analysis. Standardized [beta]-regression coefficients and their significance from multiple linear regression analysis were reported. A two-sided p value < .05 was considered statistically significant.

Table 2. Relationship between mean TIMI frame count (TFC) and clinical and laboratory parameters

| Parameter                      | r   | P*  | Beta  | P#  |
|--------------------------------|-----|-----|-------|-----|
| Age, year                      | 0.015 | .750 |       |     |
| Gender [Female], n (%)         | 0.245 | <.001 | -0.009 | .914 |
| Hypertension, n (%)            | 0.024 | .597 |       |     |
| Diabetes mellitus, n (%)       | 0.014 | .763 |       |     |
| Smoking, n (%)                 | 0.083 | .073 |       |     |
| Height, m                      | 0.257 | <.001 | 0.210 | .010 |
| Weight, kg                     | 0.172 | <.001 | 0.093 | .265 |
| BMI, kg/m²                     | 0.015 | .763 |       |     |
| Waist circumference, m         | 0.064 | .215 |       |     |
| Hip circumference, m           | 0.132 | .011 | -0.003 | .966 |
| Waist/hip ratio                | -0.095 | .069 |       |     |
| SBP, mm Hg                     | -0.111 | .020 | -0.106 | .077 |
| DBP, mm Hg                     | -0.059 | .214 |       |     |
| Heart rate, bpm                | -0.113 | .019 | -0.033 | .577 |
| Fasting blood glucose, mg/dL   | 0.100 | .038 | 0.131 | .027 |
| Total cholesterol, mg/dL       | -0.024 | .610 |       |     |
| Triglyceride, mg/dL            | 0.039 | .412 |       |     |
| HDL cholesterol, mg/dL         | -0.011 | .821 |       |     |
| LDL cholesterol, mg/dL         | -0.071 | .154 |       |     |
| Urea, mg/dL                    | 0.106 | .024 | -0.028 | .687 |
| Creatinine, mg/dL              | 0.218 | <.001 | 0.110 | .133 |
| Uric acid, mg/dL               | 0.228 | <.001 | 0.150 | .041 |
| WBC, x10⁹/L                    | 0.072 | .120 |       |     |
| Hemoglobin, g/dL               | 0.211 | <.001 | 0.082 | .239 |
| MCH, pg/cell                   | 0.093 | .064 |       |     |
| MCV, fl                        | 0.070 | .158 |       |     |
| Platelet, x10⁹/L               | -0.121 | .010 | -0.050 | .407 |
| MPV, fl                        | -0.017 | .8713 |       |     |

P* = Bivariate analysis  
P# = Multiple linear regression analysis to identify the independent predictors of mean TFC by including the parameters that were correlated with mean TFC in bivariate analysis.

A two-sided p value < .05 was considered statistically significant.

BMI - body mass index; DBP - diastolic blood pressure; HDL - high density lipoprotein; LDL - low density lipoprotein; MCH - mean corpuscular hemoglobin; MCV - mean corpuscular volume; MPV - mean platelet volume; SBP - systolic blood pressure; WBC - white blood cell.

Results

Mean TFC was 23.6±3.6 in CSF group whereas 15.7±2.6 in normal coronary flow group. Biochemical and demographic characteristics of all patients were presented on Table 1. There were no statistical differences in age, history of hypertension, and diabetes mellitus among groups (p>.05 for all). Compared to group 2, group 1 had not significantly different MPV levels (p>.05) (Table 1). Male gender and smoking was more frequent among CSF group, height, serum creatinine and uric acid levels and hemoglobin level and platelet count were associated with mean TFC (p<.05 for all). Logistic regression analysis revealed that the only independent predictors of CSF were height (Beta=0.210, p=.010) and serum uric acid level (Beta=0.150, p=.041) were independently associated with mean TFC (Table 2).

Discussion

The present study demonstrated that the MPV level is not associated with CSF in patients with SAP.

Platelet function disorders, early phases of diffuse atherosclerosis, inflammation, and imbalance of vessel active substance, impaired diastolic function as well as reduced endothelium-mediated dilation have been suggested to be involved in the development of CSF (1-13). MPV, an indicator of platelet activation, has an important role in the pathophysiology of cardiovascular diseases and it has been demonstrated that they are involved in the development of CSF (14-16). It is known that platelets having dense granules are biochemically, functionally, and metabolically more active and are risk factor for developing coronary thrombosis, leading to myocardial infarction. In comparison to smaller ones, larger platelets are associated with other markers of platelet activity, including increased platelet aggregation, increased thromboxane synthesis and beta-thromboglobulin release, and increased expression of adhesion molecules (17, 18). Elevations of MPV values have also been shown in patients with CAD, insulin resistance such as metabolic syndrome, obesity, impaired fasting glucose, diabetes mellitus, hypertension, stroke, hypercholesterolemia, and smoking suggesting a common mechanism by which these factors may increase the risk of cardiovascular disease (15, 19-22).

The general hypothesis that the pathogenesis of CSF is related to an increased MPV levels. Indeed, some studies have provided the evidence of increased MPV levels in CSF (Table 3). Şen et al. (23) have compared 84 CSF patients with 88 CAD and
80 healthy controls and reported that MPV is increased in CSF cases comparable with CAD patients. As an affirming finding, Çelik et al. (24) have compared 50 CSF patients with 50 healthy subjects and found that MPV is increased in CSF cases compared to control cases. Additionally, Elsherbiny et al. (5) have evaluated 32 CSF patients with insulin resistance, 28 CSF patients with insulin sensitive and 20 healthy controls, and reported that MPV is increased in CSF cases compared to control cases and coexistence of insulin resistance further increased MPV. In literature, only one study which Nurkalem et al. (25) evaluated the association between CSF patients with angina pectoris and MPV values. In this study, the authors have evaluated 24 CSF patients with unstable angina pectoris (USAP), 26 CSF patients with SAP and 22 healthy controls, and reported that MPV value is increased in CSF cases presented with USAP but not in CSF cases presented with SAP compared to healthy individuals.

Çelik et al. (26) have compared 57 CSF patients with 90 healthy subjects in a retrospective study and found that MPV is increased in CSF cases compared to control cases. Işık et al. (26) have compared 57 CSF patients with 90 healthy subjects in a retrospective study and found that MPV is increased in CSF cases compared to control cases. In our study, we evaluated 76 SAP patients with CSF and 389 SAP patients without CSF, and found no statistically significant differences in MPV values between among two groups. Results of the present study suggest, in contrary with the previous reports (5, 23-26), that elevated values of MPV may not play a role in pathogenesis of CSF in patients with SAP.

Multiple etiopathogenic mechanisms underlying CSF might be the basis of negative findings in the present study as several inflammatory, oxidative markers would play role in the development of CSF. Increased serum uric acid (27), circulating soluble CD40 (28), resistin (29), asymmetric dimethylarginine, homocysteine levels (30), besides decreased serum paraoxonase activity (2), serum adiponectin (31), and nitric oxide (30), levels was reported to be associated with the presence of CSF. Ahead of inflammatory and oxidative stress markers, markers of blood viscosity were also reported to be related with CSF (32).

Beyond the absence of association of MPV and the coronary blood flow in our study, we have found independent association of coronary blood flow and serum uric acid level supporting previous reports (27) and height. Height is a novel anthropometric marker of CSF, which is first to be reported and increased total coronary artery length in tall subjects might be the mechanism of the link between length and coronary blood flow in our study.

**Study limitations**

Certain limitations of the present study should be considered. First of all the study was planned as retrospective. Angiographic diagnosis of normal coronary arteries is still a debate in current cardiovascular era as contrast angiograms might underestimate the presence of atherosclerotic plaque; however we could not perform more definitive diagnostic tools. Another potential source of bias in our study was confounders of TFC such as heart rate, nitrate use and the coronary catheter size (33) although we have used same coronary catheter size and participants given nitrates and participants with extremes of heart rate were excluded from our study. As another limitation

| Publication | Group | Sample Size | MPV (FL) | P Value | Comment |
|-------------|-------|-------------|----------|---------|---------|
| Nurkalem et al, 2008 (25) | USAP with SCF | 24 | 10.10±2.10 | .007 | MPV is increased in SCF cases presented with USAP but not in SCF cases presented with SAP |
| | SAP with SCF | 26 | 8.80±2.30 | <.001 | |
| | Controls | 22 | 8.10±2.00 | <.001 | |
| Şen et al, 2009 (23) | SCF | 84 | 10.50±1.65 | .012 | MPV is increased in SCF cases comparable with CAD patients |
| | CAD | 88 | 10.43±1.55 | <.001 | |
| | Controls | 80 | 8.30±1.32 | <.001 | |
| Çelik et al, 2010 (24) | SCF | 50 | 8.20±0.70 | <.001 | MPV is increased in SCF cases compared to control cases |
| | Controls | 50 | 7.20±0.60 | <.001 | |
| Elsherbiny et al, 2012 (5) | IR SCF | 32 | 8.25±0.48 | <.01 | MPV is increased in SCF cases compared to control cases and coexistence of insulin resistance further increased MPV |
| | IS SCF | 28 | 7.55±0.25 | <.001 | |
| | Controls | 20 | 7.17±0.52 | <.001 | |
| Işık et al, 2012 (26) | SCF | 57 | 8.4±1.0 | <.001 | MPV is increased in SCF cases compared to control cases with stable angina and ischemia on non-invasive tests |
| | Controls | 90 | 7.9±0.6 | <.001 | |
| Current study | SAP with SCF | 76 | 8.73±1.27 | .881 | MPV in SCF cases is comparable with control cases in the study population of stable angina |
| | SAP without SCF | 389 | 8.76±1.43 | <.001 | |

**Note:** USAP - unstable angina pectoris; SAP - stable angina pectoris; SCF - slow coronary flow; IR - insulin resistance; IS - insulin sensitive; MPV - mean platelets volume

**Table 3.** Previously published studies to demonstrate the association between MPV and SCF
study population continued taking previously prescribed medications at the time of angiography in both groups; however two groups did not differ with regard to medications including anti-platelet drugs (none of the patients were under anticoagulant therapy, data not shown). We also should underline the fact that we had single measurement of MPV, which limits the reliability and usefulness of this assay.

Conclusion

In spite of the retrospective study design, the present study revealed -in the largest ever reported cohort- that height and serum uric acid levels are independent predictors of CSF despite the absence of association between MPV and presence of CSF contrary to previously reported studies.

Conflict of interest: None declared.

Peer-review: Externally peer-reviewed.

Authorship contributions: Concept - A.Y., Z.K.; Design - Y.S.; Supervision - R.D.; Data collection &/or processing - A.B.Y.; Analysis &/or interpretation - Ö.G.; Literature search - E.E.; Writing - H.L.A.; Critical review - Z.K.

References

1. Varol E, Gülcan M, Aylak F, Özaydın M, Sütçü R, Erdoğan D, et al. Increased neopterin levels and its association with angiographic variables in patients with slow coronary flow: an observational study. Anadolu Kardiyol Derg 2011; 11: 692-7.
2. Yıldız A, Gür M, Yılmaz R, Demirbağ R, Polat M, Selek S, et al. Association of paraxoxonase activity and coronary blood flow. Atherosclerosis 2008; 197: 257-63. [CrossRef]
3. Vrints C, Herman AG. Role of the endothelium in the regulation of coronary artery tone. Acta Cardiol 1991; 46: 399-418.
4. Gökçe M, Kaplan S, Tekelioğlu Y, Erdoğan T, Küçüksomanoğlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 2005; 28: 145-8. [CrossRef]
5. Elsherbiny IA, Shoukry A, El Tahlawi MA. Mean platelet volume and its relation to insulin resistance in non-diabetic patients with slow coronary flow. J Cardiol 2012; 59: 176-81. [CrossRef]
6. Murat SN, Duran M, Kalay N, Günebakmaz O, Akpek M, Doger C, et al. Relation between mean platelet volume and severity of atherosclerosis in patients with acute coronary syndromes. Angiology 2013; 64: 131-6. [CrossRef]
7. Duran M, Günebakmaz O, Uysal OK, Oacak A, Yılmaz Y, Arıç H, et al. The relation between mean platelet volume and coronary collateral vessels in patients with acute coronary syndromes. J Cardiol 2013; 61: 295-8. [CrossRef]
8. İnanç T, Kaya MG, Yarıoğlu M, Arıç I, Özdroğru I, Doğan A, et al. The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives. Blood Press 2010; 19: 81-5. [CrossRef]
9. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88. [CrossRef]
10. Lanza GA, Andreotti F, Sestito A, Sciacchitano A, Crea F, Maserei A. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001; 22: 1924-30. [CrossRef]
11. Tuzcu EM, Kapadia SR, Tutar E, Ziadah K, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103: 2705-10. [CrossRef]
12. Sezgin AT, Topal E, Baruşçu I, Özdemir R, Gülli H, Barışkaner E, et al. Impaired left ventricle filling in slow coronary flow phenomenon: an echo-Doppler study. Angiology 2005; 56: 397-401. [CrossRef]
13. Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J 2003; 146: 84-90. [CrossRef]
14. Park Y, Scheene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13: 301-6. [CrossRef]
15. Korkmaz L, Korkmaz AA, Akyüz AR, Ağaoğlu MT, Acar Z, Kiris A, et al. Association between mean platelet volume and coronary artery calcification in patients without overt cardiovascular disease: an observational study. Anadolu Kardiyol Derg 2012; 12: 35-9.
16. Damaske A, Muxel S, Fasola F, Radmacher MC, Schaefer S, Jabs A, et al. Peripheral hemorheological and vascular correlates of coronary blood flow. Clin Hemorheol Microcirc 2011; 49: 261-9.
17. Rao AK, Goldberg RE, Walsh PN. Platelet coagulant activities in diabetes mellitus. Evidence for relationship between platelet coagulant hyperactivity and platelet volume. J Lab Clin Med 1984; 103: 82-92.
18. Günebakmaz O, Kaya MG, Kaya EG, Arıcı I, Yarıoğlu M, Doğan O, et al. Mean platelet volume predicts embolic complications and prognosis in infective endocarditis. Int J Infect Dis 2010; 14: 982-5. [CrossRef]
19. Pizzulli L, Yang A, Martin JF, Lüderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998; 19: 80-4. [CrossRef]
20. Tavl Y, Şen N, Yaşıcı HL, Hızal F, Abacı A, Çengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007; 120: 245-50. [CrossRef]
21. Hekimsoy Z, Payzin B, Örnek T, Kandoğan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004; 18: 173-6. [CrossRef]
22. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148-56. [CrossRef]
23. Şen N, Başar N, Maden O, Özcan F, Özlı ME, Güngör O, et al. Increased mean platelet volume in patients with slow coronary flow. Platelets 2009; 20: 23-8. [CrossRef]
24. Çelik T, Yüksel UC, Bugan B, İyisoy A, Çelik M, Demirkol S, et al. Relation between mean platelet volume and coronary collateral vessels in patients with acute coronary syndromes. J Cardiol 2013; 61: 295-8. [CrossRef]
25. İnanç T, Kaya MG, Yarıoğlu M, Arıç I, Özdroğru I, Doğan A, et al. The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives. Blood Press 2010; 19: 81-5. [CrossRef]
26. Kaya et al. Mean platelet volume 23

Anatolian J Cardiol 2015; 15: 18-24

27. Yıldız A, Yılmaz R, Demirbağ R, Gür M, Baş MM, Erel O. Association of serum uric acid level and coronary blood flow. Coron Artery Dis 2007; 18: 607-13. [CrossRef]
28. Durakoğlugil ME, Kocaman SA, Çetin M, Kırbas A, Çanga A, Erdoğan T, et al. Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: an observational study. Anadolu Kardiyol Derg 2013; 13: 39-44.

29. Çanga A, Çetin M, Kocaman SA, Durakoğlugil ME, Kırbas A, Erdoğan T, et al. Increased serum resistin levels in patients with coronary slow-flow phenomenon. Herz 2013; 7: 773-8. [CrossRef]

30. Yücel H, Özaydın M, Doğan A, Erdoğan D, Türker Y, Ceyhan BM, et al. Plasma concentrations of asymmetric dimethylarginine, nitric oxide and homocysteine in patients with slow coronary flow. Scand J Clin Lab Invest 2012; 72: 495-500. [CrossRef]

31. Selçuk H, Selçuk MT, Temizhan A, Maden O, Saydam GS, Ulupınar H, et al. Decreased plasma concentrations of adiponectin in patients with slow coronary flow. Heart Vessels 2009; 24: 1-7. [CrossRef]

32. Ergun-Çağlı K, İleri-Gürel E, Özeke O, Seringeç N, Yalçinkaya A, Kocabeyoğlu S, et al. Blood viscosity changes in slow coronary flow patients. Clin Hemorheol Microcirc 2011; 47: 27-35.

33. Abacı A, Oğuzhan A, Eryol NK, Ergin A. Effect of potential confounding factors on the thrombolysis in myocardial infarction trial frame count and its reproducibility. Circulation 1999; 100: 2219-23. [CrossRef]